Pharma powerhouse Iberia Pharmaceuticals is riding a wave of early success after the launch of its science-driven skincare brand KeyCi, with the company reporting an overwhelming consumer response in its initial rollout.

 

The strong debut points to a clear shift in consumer preferences, as buyers increasingly gravitate toward research-led skincare promising results, sustainability, and inclusivity. Within just months, KeyCi has reached thousands of customers nationwide, positioning itself as a premium yet accessible offering focused on barrier repair, hydration, and long-term skin health.

 

Targeting modern consumers aged 18–45, KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval. Its initial portfolio includes four products designed specifically for Indian skin, blending daily usability with clinical-grade performance. 

 

The brand’s use of advanced liposomal delivery systems is aimed at enhancing absorption and delivering sustained, measurable results.

 

Developed over several years, the range is gender-neutral and suitable for all skin types, created through close collaboration between Iberia’s in-house scientists, dermatologists, and clinical experts to address local environmental conditions.

 

“Our vision is to become a global leader in clean beauty, and we aim to set new standards in skincare. The response we have received during the initial phase has exceeded our expectations and validates the trust that consumers place in our formulations about science-backed skincare. 

 

"Our focus has been on building formulations grounded in dermatological research and pharmaceutical standards while ensuring they are suited to Indian climatic conditions and lifestyles.” said Nitin Jain, Founder and Managing Director, Iberia Pharmaceuticals.

 

The company is now looking to build on the momentum, with plans to expand the KeyCi portfolio in the near future as demand continues to rise.

 

“Our aim with KeyCi has been to bring together clinical research, safe formulations and responsible production practices. Following the strong initial traction, the company plans to introduce new products within the portfolio in the near future. The early market response also reinforces the demand for skincare that is both scientifically formulated and mindful of sustainability.” said Saurav Ojha, Co-Founder & Whole-Time Director, Iberia Pharmaceuticals.